Establishing a new comprehensive blood test to monitor rhabdomyosarcoma in children
Dr Supriti Ghosh at The Institute of Cancer Research hopes to learn more about how to use tiny fragments of DNA from the blood to monitor rhabdomyosarcoma.
Creating innovative new treatments for childhood rhabdomyosarcoma by harnessing the body’s natural defence system
Dr Matthew Blunt aims to create and test immunotherapy treatments for rhabdomyosarcoma that are safer and more effective than chemotherapy.
Investigating a new way of treating poor-prognosis rhabdomyosarcoma
Evaluating a novel protein methyltransferase inhibitor for poor-prognosis rhabdomyosarcoma therapy
Predicting high-risk rhabdomyosarcoma at diagnosis to improve outcomes
Assessing rhabdomyosarcoma risk prediction markers based on the biological conditions in the tumour, like low oxygen levels, few blood vessels, and genetics.
Investigating the shape of fusion genes in rhabdomyosarcoma
How the 3D shape of fusion gene genetic code affects cancer cell behaviour and whether shape-modifying medicines could mitigate these effects.
Discovering what makes teenagers and young adults with soft tissue sarcomas different
Finding the biological differences between teenage and young adult cancers cells compared to older adults.
Liquid biopsies for rhabdomyosarcoma: A new way to improve rhabdomyosarcoma treatment
Looking for differences in newly diagnosed RMS patient samples to see if there are any that could be used to show whether treatments are working.
A living review of new treatments for children and young people with relapsed and refractory rhabdomyosarcoma
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
New treatments for relapsed rhabdomyosarcoma
Developing better models of rhabdomyosarcoma to test available treatments.